Login
Join for Free

All Posts

Regulatory safety experts reviewing global data to support regulatory harmonization, safety reporting consistency, and post-marketing safety oversight in multinational pharmacovigilance operations.
Picture of Mahtab Shardi

Mahtab Shardi

Harmonization in pharmacovigilance in 2026

Inspection trends show that inconsistent global safety practices remain a leading source of pharmacovigilance findings. This article explains how regulatory harmonization, aligned safety reporting, and coordinated oversight shape inspection outcomes and support compliant international pharmacovigilance operations.
  • GMP, Pharmacovigilance
Picture of Mahtab Shardi

Mahtab Shardi

Causality assessment in pharmacovigilance in 2026: Inspection Logic and Regulatory Expectations

This article explains how regulators evaluate adverse event assessment methods in pharmacovigilance inspections, why weak safety case assessment leads to repeat findings, and how structured causality analysis strengthens signal detection decision making and benefit–risk evaluation under regulatory review.
  • Compliance, GMP
Inspection in pharma
Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

Visual Inspection in Pharma (2026): What It Is, Scope, PDF Guides and SOP Essentials

Visual Inspection checks parenteral units for particles, damage, and labeling errors before release. EU GMP Annex 1 expects inspection of parenteral containers (8.30) and warns visual inspection cannot replace integrity testing, including 100% testing for fusion-sealed volumes ≤100 mL (8.22).
  • Compliance, GMP, Qualification, Validation
Wide view of a regulated pharmaceutical manufacturing facility during a quality inspection, illustrating pharmaceutical GxP compliance, GxP inspection readiness, quality risk management, data integrity expectations, and pharmaceutical governance systems.
Picture of Mahtab Shardi

Mahtab Shardi

GxP in pharma in 2026: How Inspectors Evaluate System Control

This article explains how GxP quality systems are assessed during inspections, why gaps in governance and execution lead to repeat audit findings, and how regulated pharma operations strengthen inspection readiness through risk management, data integrity, and lifecycle compliance controls.
  • Compliance, GMP
Roles in pharma industry
Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

Quality Oversight In 2026: Roles in pharma industry, GMP Expectations, And Risk-Based Control

Quality Oversight keeps GMP decisions consistent, traceable, and risk-based. It connects deviation handling, CAPA, change control, and trend reviews. It also proves management engagement through documented actions. Strong oversight reduces repeat failures and supports confident batch disposition.
  • Compliance, GMP, Qualification, Validation
Re-validation in pharma
Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

Revalidation In Pharma (2026 guide): Meaning, Triggers, Frequency, And Requalification Differences

Revalidation protects product quality and business continuity by linking GMP decisions to risk, evidence, and context. This article helps teams decide when to act, what to document, and how to classify issues consistently before audits and regulatory inspections.
  • Compliance, GMP, Qualification, Validation
Regulated pharmaceutical manufacturing facility during a quality inspection, illustrating pharmaceutical regulatory requirements, GMP compliance guidelines, operational control in GMP facilities, documentation control, and facility audit preparation under global GMP standards.
Picture of Mahtab Shardi

Mahtab Shardi

GMP Regulations in 2026: How Inspectors Assess Compliance and Control Systems

This article explains how pharmaceutical regulatory requirements shape inspection decisions, why GMP compliance gaps persist across manufacturing sites, and which operational controls, documentation practices, and risk-based measures support inspection readiness under global GMP standards.
  • Compliance, GMP
Professional standing inside a regulated pharmaceutical cleanroom, illustrating contamination control in drug manufacturing, GMP quality management system oversight, facility design and equipment qualification, and regulatory inspection readiness.
Picture of Mahtab Shardi

Mahtab Shardi

WHO GMP in 2026: Inspection Readiness and Compliance Expectations

This article explains how global pharmaceutical GMP standards are applied during inspections, why operational gaps persist despite formal compliance, and how quality systems, contamination control, and risk-based execution shape regulatory inspection readiness across manufacturing operations.
  • Compliance, GMP
Audit Findings
Picture of Ershad Moradi

Ershad Moradi

Content Marketing Specialist

Audit Observation in Pharma (2026 guide): Meaning, Types, and GMP Classification

Audit observations help pharma teams identify GMP gaps before they become bigger failures. When teams classify findings correctly, they prioritize CAPA actions faster, justify risk decisions clearly, and improve inspection readiness through stronger evidence, ownership, and effectiveness checks across operations.
  • Blog, Compliance, GMP
GMP Environments
Picture of Mahtab Shardi

Mahtab Shardi

GMP Environments in 2026: Inspection Readiness and Control Expectations

This article explains how inspectors evaluate GMP environments during regulatory inspections, why environmental findings often repeat, and how facility design, flow control, monitoring, and risk-based controls shape inspection readiness in real pharmaceutical manufacturing operations.
  • Compliance, GMP